Association analyses identify 31 new risk loci for colorectal cancer susceptibility. by Law, PJ et al.
ARTICLE
Association analyses identify 31 new risk loci for
colorectal cancer susceptibility
Philip J. Law, Maria Timofeeva, Ceres Fernandez-Rozadilla et al.#
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a
strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases
and 71,379 controls of European ancestry that identiﬁes SNPs at 31 new CRC risk loci. We
also identify eight independent risk SNPs at the new and previously reported European CRC
loci, and a further nine CRC SNPs at loci previously only identiﬁed in Asian populations. We
use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods
to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate
target genes that are enriched for known CRC pathways such as Wnt and BMP, they also
highlight novel pathways with no prior links to colorectal tumourigenesis. These ﬁndings
provide further insight into CRC susceptibility and enhance the prospects of applying genetic
risk scores to personalised screening and prevention.
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Many colorectal cancers (CRC) develop in geneticallysusceptible individuals1 and genome-wide associationstudies (GWAS) of CRC have thus far reported 43 SNPs
mapping to 40 risk loci in European populations2,3. In Asians, 18
SNPs mapping to 16 risk loci have been identiﬁed4,5, a number of
which overlap with those reported in Europeans. Collectively
across ethnicities GWAS has provided evidence for 53 unique
CRC susceptibility loci. While much of the heritable risk of CRC
remains unexplained, statistical modelling indicates that further
common risk variants remain to be discovered6.
To gain a more comprehensive insight into CRC aetiology, we
conducted a GWAS meta-analysis that includes additional,
unreported datasets. We examine the possible gene regulatory
mechanisms underlying all GWAS risk loci by analysing in situ
promoter Capture Hi-C (CHi-C) to characterise chromatin
interactions between predisposition loci and target genes, exam-
ine gene expression data and integrate these data with chromatin
immunoprecipitation-sequencing (ChIP-seq) data. Finally, we
quantify the contribution of the loci identiﬁed in this study,
together with previously identiﬁed loci to the heritable risk of
CRC and estimate the sample sizes required to explain the
remaining heritability.
Results
Association analysis. Thus far, studies have identiﬁed 61 SNPs
that are associated with CRC risk in European and Asian popu-
lations (Supplementary Data 1). To identify additional CRC risk
loci, we conducted ﬁve new CRC GWAS, followed by a meta-
analysis with 10 published GWAS totalling 34,627 cases and
71,379 controls of European ancestry under the auspices of the
COGENT (COlorectal cancer GENeTics) consortium7 (Fig. 1,
Supplementary Data 2). Following established quality control
measures for each dataset8 (Supplementary Data 3), the geno-
types of over 10 million SNPs in each study were imputed, pri-
marily using 1000 Genomes and UK10K data as reference (see
Methods). After ﬁltering out SNPs with a minor allele frequency
<0.5% and imputation quality score <0.8, we assessed associations
between CRC status and SNP genotype in each study using
logistic regression. Risk estimates were combined through an
inverse-variance weighted ﬁxed-effects meta-analysis. We found
little evidence of genomic inﬂation in any of the GWAS datasets
(individual λGC values 1.01–1.11; meta-analysis λ1000= 1.01,
Supplementary Figure 1).
Excluding ﬂanking regions of 500 kb around each previously
identiﬁed CRC risk SNP, we identiﬁed 623 SNPs associated with
CRC at genome-wide signiﬁcance (logistic regression, P < 5 × 10−8).
After implementing a stepwise model selection, these SNPs were
resolved into 31 novel risk loci, with 27 exhibiting Bayesian False
Discovery Probabilities (BFDPs)9 <0.1 (Table 1, Fig. 2, Supplemen-
tary Figure 2). The association at 20q13.13 (rs6066825) had only
been previously identiﬁed as signiﬁcant in a multi-ethnic study10.
Two new associations (rs3131043 and rs9271770) were identiﬁed
within the 6p21.33 major histocompatibility (MHC) region, with
rs3131043 located 470 kb 5′ of HLA-C, and rs9271770 located
between HLA-DRB1 and HLA-DQA1. Imputation of the MHC
region using SNP2HLA11 provided no evidence for additional
MHC risk loci.
We conﬁrmed 28 of the 40 risk loci for CRC published as
genome-wide signiﬁcant in Europeans (i.e. P < 5 × 10−8) (Supple-
mentary Data 1). For four previously reported risk loci2,12–14, we
observed associations that were just below genome-wide signiﬁ-
cance (3q26.2, rs10936599, P= 1.41 × 10−7; 12p13.32, rs3217810,
P= 1.09 × 10−6; 16q22.1, rs9929218, P= 4.96 × 10−7; 16q24.1,
rs2696839, 1.28 × 10−6). In contrast, there was limited support in
our current study for eight of the associations previously reported
by others2,10,15–17 (2q32.3, rs11903757, P= 0.23; 3p14.1, rs812481,
P= 0.44; 4q22.2, rs1370821, P= 3.41 × 10−5; 4q26, rs3987, P=
0.10; 4q32.2, rs35509282, P= 0.24; 10q11.23, rs10994860, P=
3.65 × 10−4; 12q24.22, rs73208120, P= 0.03; 20q11.22, rs2295444,
P= 0.03), all having a BFDP >0.99 (Supplementary Data 1). Of the
16 reported Asian-speciﬁc loci4,5, nine harboured genome-wide
signiﬁcant signals in the current study (all BFDP <0.06), albeit
sometimes at SNPs with low r2 but high D′ with the original SNP
in Europeans, consistent with differences in allele frequencies in
the different populations (Supplementary Data 1). Conditioning on
the reported Asian SNPs, ﬁve of the nine European risk SNPs were
independent of the Asian SNP (Pconditional < 5 × 10−8, Supplemen-
tary Data 4). We found no evidence of association signals at the
remaining previously reported Asian SNPs.
Next, we performed an analysis conditioned on the sentinel
SNP (r2 < 0.1 and Pconditional < 5 × 10−8; Table 2) to search for
further independent signals at these new and previously reported
risk loci. We conﬁrmed the presence of previously reported dual
signals at 14q22.2, 15q13.3 and 20p12.318. For the new risk loci,
an additional independent signal was identiﬁed at 5p15.3. In
addition, a further seven signals were found at ﬁve previously
reported risk loci: 11q13.4, 12p13.32, 15q13.3, 16q24.1, 20q13.13.
Two of these signals were at the 15q13.3 locus, of which one was
5′ of GREM1 and the other intronic to FMN1. A further two
signals were proximal and distal of 20q13.13. At 12p13.32 and
16q24.1, genome-wide associations marked by rs12818766 and
rs899244, respectively, were shown. These were independent of
the previously reported associations2,14 at rs3217810 and
rs2696839 (pairwise r2= 0.0).
In total, we identiﬁed 39 new independent SNPs associated
with CRC susceptibility at genome-wide signiﬁcance in Eur-
opeans. Together with the nine associations previously identiﬁed
in Asian populations, and the 31 previously identiﬁed SNPs that
were conﬁrmed here, this brought the number of identiﬁed CRC
association signals in Europeans to 79. Several of these risk loci
map to regions previously identiﬁed in other cancers. In
particular, three regions harbour susceptibility loci for multiple
cancers19, speciﬁcally 5p15.33 (TERT-CLPTM1L), 9p21.3
(CDKN2A) and 20q13.33 (RTEL1) (Supplementary Data 5).
Functional annotation and biological inference of risk loci. To
the extent that they have been deciphered, most GWAS risk loci map
to non-coding regions of the genome inﬂuencing gene regulation19.
Consistent with this, we found evidence that the CRC risk SNPs
mapped to regions enriched for active enhancer marks (H3K4me1
and H3K27ac) in colonic crypts (permutation test, P= 0.034 and
0.033, respectively) and colorectal tumours (P= 4.2 × 10−3 and
4.0 × 10−5) (Supplementary Figure 3). To determine whether the
CRC SNPs overlapped with active regulatory regions in a cell-type
speciﬁc manner20, we analysed the H3K4me3, H3K27ac, H3K4me1,
H3K27me3, H3K9ac, H3K9me3 and H3K36me3 chromatin marks
across multiple cell types from the NIH Roadmap Epigenomics
project21. Colonic and rectal mucosa cells showed the strongest
enrichment of risk SNPs at active enhancer and promoter regions
(H3K4me3, H3K4me1 and H3K27ac marks, P < 5 × 10−4) (Supple-
mentary Figure 3).
Given our observation that the risk loci map to putative
regulatory regions, we examined both histone modiﬁcations and
transcription factor (TF) binding sites in LoVo and HT29 CRC
cells across the risk SNPs. Using variant set enrichment22, we
identiﬁed regions of strong LD (deﬁned as r2 > 0.8 and D′ > 0.8)
with each risk SNP and determined the overlap with ChIP-seq
data from the Systems Biology of Colorectal cancer (SYSCOL)
study and inhouse-generated histone data. We identiﬁed an
over-representation of binding for MYC, ETS2, cohesin loading
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factor NIPBL and cohesin-related proteins RAD21, SMC1A and
SMC3 (Supplementary Figure 4). About 87% (69/79) of the risk
SNPs were predicted to disrupt binding motifs of speciﬁc TFs,
notably CTCF, SOX and FOX, with 35% located within TF
binding peaks from LoVo, HT29 or ENCODE ChIP-seq data
(Supplementary Data 6).
The upstream mechanisms by which predisposition SNPs
inﬂuence disease risk is often through effects on cis-regulatory
transcriptional networks, speciﬁcally through chromatin-looping
interactions that are fundamental for regulation of gene expres-
sion. Therefore, to link regulatory regions containing risk SNPs to
promoters of candidate target genes, we applied in situ promoter
capture Hi-C (CHi-C) data in LoVo and HT29 cells (Supplemen-
tary Data 9). About 38% of the risk SNPs mapped to regions that
showed statistically signiﬁcant chromatin-looping interactions
with the promoters of respective target genes. Notably, as well
as conﬁrming the interaction between rs6983267 and MYC at
8q24.21 (Supplementary Figure 2), the looping interaction from
an active enhancer region at 10q25.2 implicates TCF7L2 as the
target gene of rs12255141 variation (Fig. 3). TCF7L2 (previously
known as TCF4) is a key transcription factor in the Wnt pathway
and plays an important role in the development and progression
of CRC23. Intriguingly, TCF7L2 has been shown to bind to aMYC
enhancer containing rs698326724 and to a GREM1 enhancer near
rs1696968125. Based on ChromHMM, this region is annotated as
a promoter in HCT116 cells, but not in normal colonic and rectal
mucosa. Additionally this locus has been implicated in lung
cancer26 and low-grade glioma27. Similarly, the 9p21.3 chromatin
interaction provides evidence to support CDKN2B as the target
gene for rs1412834 variation, a region of somatic loss.
We sought to gain further insight into the target genes at each
locus, and hence the biological mechanisms for the associations,
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by performing expression quantitative trait locus (eQTL) analysis
in colorectal tissue. We analysed inhouse eQTL data generated
from samples of normal colonic mucosa (INTERMPHEN study,
n= 131 patients) and GTEx data from transverse colon (n=
246). For the previously identiﬁed risk loci, there were eQTLs for
rs4546885 and LAMC1 (1q25.3), rs13020391 and lnc-RNA
RP11–378A13.1 (2q35), and rs3087967 and COLCA1, COLCA2
and C11orf53 (11q23.1). Amongst the eQTL associations at the
new risk loci, pre-eminent eQTLs were rs9831861 and SFMBT1
(3p21.1), rs12427600 and SMAD9 (13q13.3), and rs12979278 and
FUT2 and MAMSTR (19q13.33) (Supplementary Data 7). How-
ever, while multiple nominally signiﬁcant cis-eQTLs were present,
nearly half of all loci had no evidence of cis-eQTLs in the sample
sets used.
In addition to eQTL analysis, we performed Summary-data-
based Mendelian Randomization (SMR) analysis28 as a more
stringent test for causal differences in gene transcription
(Supplementary Data 8). There was support for the 11q23.1
locus SNP inﬂuencing CRC risk through differential expression of
one or more of COLCA1, COLCA2 and C11orf53 transcripts
(PSMR < 10−10). There was also evidence that the 3p21.1 and
19q13.33 SNPs acted through SFMBT1 and FUT2, respectively,
(PSMR < 10−5), as well as the 6p21.31 SNP acted through class II
HLA expression (PSMR < 5 × 10−4).
Based on genetic ﬁne-mapping and functional annotation, our
data indicated several candidate target genes with functions
previously unconnected to colorectal tumourigenesis
(Supplementary Data 9). The SFMBT1 protein (3p21.1) acts as
a histone reader and a component of a transcriptional repressor
complex29. TNS3 at 7p12.3 encodes the focal adhesion protein
TENSIN3, to which the intestinal stem cell marker protein
Musashi1 has been reported to bind. Tns3-null mice exhibit
impaired intestinal epithelial development, probably because of
defects in Rho GTPase signalling and cell adhesion30. LRP1
(12q13.3, LDL receptor-related protein 1) (Fig. 3) may be
involved in Wnt-signalling31, although its role in the intestines
has not previously been conclusively demonstrated. FUT2 at
19q13.33 encodes fucosyltransferase II. Variation at this locus is
associated with differential interactions with intestinal bacteria
and viruses. Our data thus provide evidence for a role of the
microbiome in CRC risk32. PTPN1 (20q13.13), also known as
PTP1B, encodes a non-receptor tyrosine phosphatase involved in
regulating JAK-signalling, IR, c-Src, CTNNB1, and EGFR.
We annotated all risk loci with ﬁve types of functional data:
(i) presence of a CHi-C contact linking to a gene promoter, (ii)
presence of an association from eQTL, (iii) presence of a
regulatory state, (iv) evidence of TF binding, and (v) presence
of a nonsynonymous coding change (Supplementary Data 9).
Collectively this analysis suggested three primary candidate
disease mechanisms across a number of risk loci: ﬁrstly, genes
linked to BMP/TGF-β signalling (e.g. GREM1, BMP2, BMP4,
SMAD7, SMAD9); secondly, genes with roles either directly or
indirectly linked to MYC (e.g. MYC, TCF7L2); and thirdly
genes with roles in maintenance of chromosome integrity (e.g.
Table 1 Summary results for the new colorectal cancer risk loci in Europeans
SNP Cytoband Position (bp,
GRCh37)
Risk/alt
allele
RAF OR 95% CI P-value BFDP I2 (%) Phet Average
info score
rs61776719 1p34.3 38,461,319 C/A 0.45 1.07 (1.05; 1.10) 2.19 × 10−10 1.98 × 10−3 1 0.44 0.89
rs12143541 1p32.3 55,247,852 G/A 0.15 1.10 (1.06; 1.13) 9.44 × 10−10 7.44 × 10−3 16 0.28 0.95
rs11692435 2q11.2 98,275,354 G/A 0.90 1.12 (1.07; 1.16) 1.22 × 10−8 0.079 29 0.14 0.97
rs11893063 2q33.1 199,601,925 A/G 0.47 1.07 (1.04; 1.09) 9.34 × 10−9 0.069 43 0.04 0.96
rs7593422 2q33.1 200,131,695 T/A 0.55 1.07 (1.05; 1.10) 3.56 × 10−11 3.50 × 10−4 15 0.28 0.99
rs9831861 3p21.1 53,088,285 G/T 0.59 1.07 (1.05; 1.09) 4.17 × 10−10 3.72 × 10−3 0 0.87 0.99
rs12635946 3q13.2 112,916,918 C/T 0.62 1.08 (1.06; 1.10) 1.02 × 10−11 1.03 × 10−4 11 0.33 0.97
rs17035289 4q24 106,048,291 T/C 0.83 1.10 (1.07; 1.13) 2.73 × 10−10 2.30 × 10−3 0 0.95 1.00
rs75686861 4q31.21 145,621,328 A/G 0.10 1.12 (1.08; 1.16) 1.76 × 10−9 0.014 0 0.49 0.92
rs2070699 6p24.1 12,292,772 T/G 0.48 1.07 (1.04; 1.09) 3.88 × 10−9 0.031 29 0.14 0.95
rs3131043 6p21.33 30,758,466 G/A 0.43 1.07 (1.05; 1.1) 2.67 × 10−8 0.159 60 0.01 0.91
rs9271770 6p21.32 32,594,248 A/G 0.81 1.08 (1.05; 1.11) 3.60 × 10−8 0.192 0 0.91 0.93
rs6928864 6q21 105,966,894 C/A 0.91 1.13 (1.09; 1.19) 1.37 × 10−8 0.094 0 0.73 0.98
rs10951878 7p12.3 46,926,695 C/T 0.49 1.06 (1.04; 1.09) 1.10 × 10−8 0.080 0 0.65 0.99
rs3801081 7p12.3 47,511,161 G/A 0.68 1.08 (1.06; 1.11) 2.00 × 10−11 1.96 × 10−4 50 0.01 1.00
rs1412834 9p21.3 22,110,131 T/C 0.50 1.08 (1.06; 1.11) 4.13 × 10−14 5.05 × 10−7 14 0.30 1.00
rs4450168 11p15.4 10,286,755 C/A 0.17 1.10 (1.06; 1.13) 1.24 × 10−8 0.079 0 0.81 0.86
rs7398375 12q13.3 57,540,848 C/G 0.72 1.09 (1.06; 1.13) 3.91 × 10−10 3.23 × 10−3 0 0.93 0.83
rs12427600 13q13.3 37,460,648 C/T 0.24 1.09 (1.06; 1.11) 5.43 × 10−11 5.01 × 10−4 0 0.81 0.99
rs45597035 13q22.1 73,649,152 A/G 0.64 1.08 (1.05; 1.10) 2.16 × 10−10 1.94 × 10−3 0 0.53 0.96
rs1330889 13q22.3 78,609,615 C/T 0.87 1.11 (1.07; 1.14) 6.50 × 10−10 5.25 × 10−3 0 0.59 0.97
rs7993934 13q34 111,074,915 T/C 0.65 1.08 (1.05; 1.10) 3.03 × 10−11 2.94 × 10−4 0 0.55 0.99
rs4776316 15q22.31 67,007,813 A/G 0.73 1.08 (1.05; 1.10) 1.11 × 10−8 0.076 22 0.21 0.95
rs10152518 15q23 68,177,162 G/A 0.19 1.08 (1.05; 1.11) 3.24 × 10−8 0.180 0 0.84 0.97
rs7495132 15q26.1 91,172,901 T/C 0.12 1.11 (1.07; 1.14) 7.92 × 10−10 6.34 × 10−3 29 0.14 0.99
rs61336918 16q23.2 80,007,266 A/T 0.29 1.09 (1.06; 1.12) 2.04 × 10−12 2.14 × 10−5 0 0.90 0.99
rs1078643 17p12 10,707,241 A/G 0.77 1.09 (1.06; 1.12) 4.14 × 10−11 3.81 × 10−4 0 0.56 0.92
rs285245 19p13.11 16,420,817 T/C 0.11 1.11 (1.07; 1.15) 3.71 × 10−8 0.195 2 0.42 0.91
rs12979278 19q13.33 49,218,602 T/C 0.53 1.07 (1.05; 1.09) 6.11 × 10−10 5.35 × 10−3 15 0.28 0.96
rs6066825 20q13.13 47,340,117 A/G 0.65 1.10 (1.08; 1.13) 3.82 × 10−17 5.67 × 10−10 0 0.49 0.99
rs3787089 20q13.33 62,316,630 C/T 0.32 1.07 (1.05; 1.10) 5.80 × 10−9 0.043 0 0.80 0.96
Associations previously only identiﬁed in Asian populations
rs639933 5q31.1 134,467,751 C/A 0.38 1.07 (1.05; 1.10) 1.14 × 10−9 9.50 × 10−3 0 0.73 0.98
rs6933790 6p21.1 41,672,769 T/C 0.83 1.10 (1.07; 1.14) 3.65 × 10−10 3.03 × 10−3 21 0.23 0.91
rs704017 10q22.3 80,819,132 G/A 0.60 1.10 (1.08; 1.13) 2.96 × 10−16 4.15 × 10−9 23 0.21 0.95
rs12255141 10q25.2 114,294,892 G/A 0.10 1.11 (1.07; 1.15) 2.97 × 10−9 0.022 0 0.81 0.96
rs10849438 12p13.31 6,412,036 G/T 0.12 1.12 (1.08; 1.16) 1.04 × 10−10 9.49 × 10−4 21 0.23 0.95
rs73975588 17p13.3 816,741 A/C 0.87 1.10 (1.06; 1.13) 8.71 × 10−9 0.058 33 0.11 0.97
rs9797885 19q13.2 41,873,001 G/A 0.71 1.08 (1.05; 1.10) 2.77 × 10−10 2.43 × 10−3 0 0.70 0.99
rs6055286 20p12.3 7,718,045 A/G 0.15 1.11 (1.07; 1.14) 9.69 × 10−11 8.61 × 10−4 50 0.02 0.97
rs2179593 20q13.12 42,660,286 A/C 0.72 1.07 (1.05; 1.10) 4.62 × 10−9 0.035 0 0.67 0.97
BFDP calculated using prior= 10−5 and maximum relative risk= 1.2
RAF risk allele frequency in Europeans, OR odds ratio, CI conﬁdence interval, BFDP Bayesian False Discovery Probability, I2 proportion of the total variation due to heterogeneity, PhetP-value for
heterogeneity
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TERT, RTEL1) and DNA repair (e.g. POLD3) (Supplementary
Figure 5).
Pathway gene set enrichment analyses33 revealed several
growth or development related pathways were enriched, notably
TGF-β signalling and immune response pathways (Supplemen-
tary Figure 6, Supplementary Data 10). Other cancer-related
themes included apoptosis and leukocyte differentiation path-
ways. We used Data-driven Expression-Prioritized Integration for
Complex Traits (DEPICT)34 to predict gene targets based on gene
functions that are shared across genome-wide signiﬁcant risk loci,
as well as those associated at P < 10−5 as advocated to mitigate
against type II error. Tissue-speciﬁcity with respect to colonic
tissue was evident (permutation test, P < 5 × 10−3) and among the
protein-coding genes predicted, there was enrichment for TGF-β
and PI3K-signalling pathways, and abnormal intestinal crypt gene
sub-networks (P < 10−5; Supplementary Data 11).
Contribution of risk SNPs to heritability. Using Linkage Dis-
equilibrium Adjusted Kinships (LDAK)35 in conjunction with the
GWAS data generated on unselected CRC cases (i.e. COIN,
CORSA, Croatia, DACHS, FIN, SCOT, Scotland1, SOCCS/LBC,
SOCCS/GS, UKBB, VQ58 studies) we estimated that the herit-
ability of CRC attributable to all common variation is 0.29 (95%
conﬁdence interval: 0.24–0.35). To estimate the sample size
required to explain a greater proportion of the GWAS heritability,
we implemented a likelihood-based approach using association
statistics in combination with LD information to model the
effect-size distribution36, which was best represented by a three-
component model (mixture of two normal distributions). Under
this model, to identify SNPs explaining 80% of the GWAS her-
itability, it is likely to require effective sample sizes in excess of
300,000 if solely based on GWAS associations (Supplementary
Figure 7).
After adjusting for winner’s curse37, the 79 SNPs thus far
shown to be associated with CRC susceptibility in Europeans
explain 11% of the 2.2-fold familial relative risk (FRR)38, whilst all
common genetic variants identiﬁable through GWAS could
explain 73% of the FRR. Thus, the identiﬁed susceptibility SNPs
collectively account for approximately 15% of the FRR of CRC
that can be explained by common genetic variation. We
incorporated the newly identiﬁed SNPs into risk prediction
models for CRC and derived a polygenic risk score (PRS) based
on a total of 79 GWAS signiﬁcant risk variants. Individuals in the
top 1% have a 2.6-fold increased risk of CRC compared with the
population average (Supplementary Figure 8). Risk re-
classiﬁcation using this PRS offers the prospect of optimising
prevention programmes for CRC in the population, for example
through targeting screening6, and also preventative interventions.
The identiﬁcation of further risk loci through the analysis of even
larger GWAS is likely to improve the performance of any
PRS model.
Co-heritability with non-cancer traits. We implemented cross-
trait LD score regression39 to investigate co-heritability globally
between CRC and 41 traits with publicly available GWAS sum-
mary statistics data. None of the genetic correlations remained
signiﬁcant after Bonferroni correction (two-sided Z-test, P-
threshold: 0.05/41= 1.2 × 10−3). However, nominally signiﬁcant
positive associations with CRC risk (Supplementary Data 12)
included insulin resistance, comprising raised fasting insulin,
glucose and HbA1c (positive), hyperlipidaemia, comprising raised
total cholesterol and low-density lipoprotein cholesterol, and
ulcerative colitis, all of which are traits or diseases previously
reported in observational epidemiological studies to be associated
with CRC risk40,41.
Discussion
Here we report a comprehensive analysis that sheds new light on
the molecular basis of genetic risk for a common cancer, and
greatly increases the number of known CRC risk SNPs. To
identify the most credible target genes at each site, we have
performed detailed annotation using public databases, and have
also acquired our own disease-speciﬁc data from ChIP-seq, pro-
moter capture Hi-C and gene expression analyses.
Given that there remains signiﬁcant missing common herit-
ability for CRC, additional GWAS meta-analyses are likely to lead
to discovery of more risk loci. Such an assertion is directly sup-
ported a contemporaneous study42, which has reported the
identiﬁcation of 40 independent signals; 30 novel loci and 10
conditionally independent association signals at previously and
newly identiﬁed CRC risk loci. Of these, 18 were replicated in our
analysis, with an additional ﬁve exhibiting an independent signal
present at the same locus (Supplementary Data 13).
Overall, our ﬁndings provide new insights into the biological
basis of CRC, not only conﬁrming the importance of established
gene networks, but also providing evidence that point to a role for
the gut microbiome in CRC causation, and identifying several
functional mechanisms previously unsuspected of any involve-
ment in colorectal tumourigenesis. Several of the gene pathways
identiﬁed through GWAS may provide potential novel targets for
chemoprevention and chemotherapeutic intervention.
Methods
Ethics. Collection of patient samples and associated clinico-pathological infor-
mation was undertaken with written informed consent and relevant ethical review
board approval at respective study centres in accordance with the tenets of the
Declaration of Helsinki. Speciﬁcally: (i) UK National Cancer Research Network
Multi-Research Ethics Committee (02/0/097 [NSCCG], 01/0/5) [SOCCS], 05/
S1401/89 [GS:SFHS], LREC/1998/4/183 [LBC1921], 2003/2/29 [LBC1936], 17/SC/
0079 [CORGI] and 07/S0703/136 [SCOT]); (ii) The research activities of UK
Biobank were approved by the North West Multi-centre Research Ethics Com-
mittee (11/NW/0382) in relation to the process of participant invitation, assess-
ment and follow-up procedures. Additionally, ethics approvals from the National
Information Governance Board for Health & Social Care in England and Wales
and approval from the Community Health Index Advisory Group in Scotland were
also obtained to gain access to the information that would allow the invitation of
participants. This study did not need to re-contact the participants, and no separate
ethics approval was required according to the Ethics and Governance Framework
(EGF) of UK Biobank; (iii) South East Ethics Committee MREC (03/1/014); (iv)
Written informed consent was obtained from all participants of CORSA. The study
was approved by the ethical review committee of the Medical University of Vienna
(MUW, EK Nr. 703/2010) and the “Ethikkommission Burgenland” (KRAGES, 33/
2010) and (v) Finnish National Supervisory Authority for Welfare and Health,
National Institute for Health and Welfare (THL/151/5.05.00/2017), the Ethics
Committee of the Hospital District of Helsinki and Uusimaa (HUS/408/13/03/03/
09).
The diagnosis of colorectal cancer (ICD-9 153, 154; ICD-10 C18.9, C19, C20)
was established in all cases in accordance with World Health Organization
guidelines.
Primary GWAS. We analysed data from ﬁve primary GWAS (Supplementary
Data 2 and Supplementary Data 3):
(1) The NSCCG-OncoArray GWAS comprised 6240 cases ascertained through
the National Study of Colorectal Cancer Genetics (NSCCG)43 and 1041 cases
collected through the CORGI consortium, genotyped using the Illumina
OncoArray. Patients were selected for having a family history of CRC (at
least one ﬁrst-degree relative) or age of diagnosis below 58. Controls were
also genotyped using the OncoArray and comprised (i) 3031 cancer-free
men recruited by the PRACTICAL Consortium—the UK Genetic Prostate
Cancer Study (UKGPCS) (age <65 years), a study conducted through the
Royal Marsden NHS Foundation Trust and SEARCH (Study of Epidemiol-
ogy & Risk Factors in Cancer), recruited via GP practices in East Anglia
(2003–2009) and (ii) 4,488 cancer-free women across the UK, recruited via
the Breast Cancer Association Consortium (BCAC).
(2) The SCOT GWAS comprised 3076 cases from the Short Course Oncology
Treatment (SCOT) trial—a study of adjuvant chemotherapy in colorectal
cancer by the CACTUS and OCTO groups44. Controls comprised 4349
cancer-free individuals from The Heinz Nixdorf Recall study45. Both cases
and controls were genotyped using the Illumina Global Screening Array.
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Fig. 2 Manhattan plot showing all loci containing genetic risk variants independently associated with colorectal cancer risk at P < 5 × 10−8 in European
populations. SNPs on the left of the plot are new SNPs identiﬁed in this study, and SNPs on the right were identiﬁed in previous studies and replicated at
genome-wide signiﬁcance in this study. The 79 risk SNPs consisted of 31 previously reported SNPs, 39 new risk SNPs, and nine SNPs previously identiﬁed
in Asian but not in European populations (denoted in dark gold). Dotted lines indicate SNPs that were identiﬁed as independent through conditional
analysis. Square brackets indicate the position of the sentinel SNP relative to nearest genes (“gene1-[]-gene2” for intergenic SNPs, “[gene]” for intragenic
SNPs). The distance from the sentinel SNP to each gene is proportional to the number of dashes. The red line indicates the genome-wide signiﬁcance
threshold. The x-axis represents the −log10P-values of the SNPs, and the y-axis represents the chromosomal positions
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(3) SOCCS/Generation Scotland (SOCCS/GS) comprised 4772 cases from the
Study of Colorectal Cancer in Scotland (SOCCS)12,13 and 12,158 controls
including 2221 population-based controls from SOCCS and additional 9937
population controls without prior history of colorectal cancer from
Generation Scotland-Scottish Family Health Study (GS:SFHS)46.
(4) SOCCS/Lothian Birth Cohort (SOCCS/LBC) GWAS comprised 1037 cases
from the Study of Colorectal Cancer in Scotland (SOCCS)47 and 1522
population-based controls without prior history of malignant tumours from
the Lothian Birth Cohorts (LBC) of 1921 and 193648.
(5) UK Biobank (UKBB) GWAS comprised 6360 cases and 25,440 population-
based control individuals. UK Biobank is a large cohort study with more
than 500,000 individuals recruited. Biological samples of these participants
were genotyped using the custom-designed Affymetrix UK BiLEVE Axiom
array on an initial 50,000 participants and Affymetrix UK Biobank Axiom
array on the remaining 450,000 participants. The two arrays had over 95%
common content. Genotyping was done at the Affymetrix Research Services
Laboratory in Santa Clara, California, USA. Details on genotyping and
quality control were previously reported49. Self-reported cases of cancers of
bowel, colon or rectum, if not conﬁrmed by the ICD9 or ICD10 codes were
excluded from the analysis. Healthy control individuals without history of
cancer and/or colorectal adenoma were included in the analysis after
matching one case to four controls by age, gender, date of blood draw,
ethnicity and region of residence (two ﬁrst letters of postal code).
Published GWAS. We made use of 10 previously published GWAS (Supple-
mentary Data 2): (1) UK1 (CORGI study) comprised 940 cases with colorectal
neoplasia and 965 controls12; (2) Scotland1 (COGS study) included 1012 CRC
cases and 1012 controls12; (3) VQ58 comprised 1800 cases from the UK-based
VICTOR and QUASAR2 adjuvant chemotherapy clinical trials and 2690 popula-
tion control genotypes from the Wellcome Trust Case Control Consortium 2
(WTCCC2) 1958 birth cohort50; (4) CCFR1 comprised 1290 familial CRC cases
and 1055 controls from the Colon Cancer Family Registry (CCFR)15; (5) CCFR2
included a further 796 cases from the CCFR and 2236 controls from the Cancer
Genetic Markers of Susceptibility (CGEMS) studies of breast and prostate
cancer51,52; (6) COIN was based on 2244 CRC cases ascertained through two
independent Medical Research Council clinical trials of advanced/metastatic CRC
(COIN and COIN-B)53 and controls comprised 2162 individuals from the UK
Blood Service Control Group genotyped as part of the WTCCC2; (7) Finnish
GWAS (FIN)3 was based on 1172 CRC cases and 8266 cancer-free controls
ascertained through FINRISK, Health 2000, Finnish Twin Cohort and Helsinki
Birth Cohort Studies; (8) CORSA (COloRectal cancer Study of Austria) a molecular
epidemiological study of 978 cases and 855 colonoscopy-negative controls54; (9)
DACHS (Darmkrebs: Chancen der Verhütung durch Screening)55 based on 1105
cases and 700 controls and (10) Croatia consisted of 764 cases and 460 population-
based controls56.
The VQ58, UK1 and Scotland1 GWAS were genotyped using Illumina Hap300,
Hap240S, Hap370, Hap550 or Omni2.5 M arrays. 1958BC genotyping was
performed as part of the WTCCC2 study on Hap1.2M-Duo Custom arrays. The
CCFR samples were genotyped using Illumina Hap1M, Hap1M-Duo or Omni-
express arrays. CGEMS samples were genotyped using Illumina Hap300 and
Hap240 or Hap550 arrays. The COIN cases were genotyped using Affymetrix
Axiom Arrays and the Blood Service controls were genotyped using Affymetrix 6.0
arrays. FIN cases were genotyped using Illumina HumanOmni 2.5M8v1 and
controls using Illumina HumanHap 670k and 610k arrays. DACHS study samples
were genotyped using the Illumina OncoArray, CORSA study sampels were
genotyped on the Affymetrix Axiom Genome-Wide CEU 1 Array, and Croatia
study samples were genotyped on Illumina OmniExpressExome BeadChip 8v1.1
or 8v1.3.
Quality control. Standard quality control (QC) measures were applied to each
GWAS8. Speciﬁcally, individuals with low SNP call rate (<95%) as well as indivi-
duals evaluated to be of non-European ancestry (using the HapMap version 2 CEU,
JPT/CHB and YRI populations as a reference) were excluded (Supplementary
Figure 9). For apparent ﬁrst-degree relative pairs, we excluded the control from a
case-control pair; otherwise, we excluded the individual with the lower call rate.
SNPs with a call rate <95% were excluded as were those with a MAF <0.5% or
displaying signiﬁcant deviation from Hardy–Weinberg equilibrium (P < 10−5). QC
details are provided in Supplementary Data 3. All genotype analyses were per-
formed using PLINK v1.957.
Imputation and statistical analysis. Prediction of the untyped SNPs was carried
out using SHAPEIT v2.83758 and IMPUTE v2.3.259. The CCFR1, CCFR2, COIN,
CORSA, Croatia, NSCCG-OncoArray, SCOT, Scotland1, SOCCS/GS, SOCCS/LBC,
UK1 and VQ58 samples used a merged reference panel using data from 1000
Genomes Project (phase 1, December 2013 release) and UK10K (April 2014
release). Imputation of UKBB was based on data from 1000 Genomes Project
(phase 3), UK10K and Haplotype Reference Consortium. The FIN and DACHS
GWAS were imputed using a reference panel comprised of 1000 Genomes Projects
Table 2 Colorectal cancer variants identiﬁed in analysis conditioning on the sentinel SNP at each risk locus
Conditional
(Sentinel) SNPs
Cytoband
(position (bp,
GRCh37))
Risk/
Alt Allele
RAF OR
(95% CI)
P-
value
Conditional
OR
(95% CI)
Conditional
P-value
BFDP LD with
sentinel
SNP (r2;
D’)
I2 (%) Phet Average
info score
rs77776598
(rs2735940)
5p15.33
(1,240,998)
C/T 0.06 1.14
(1.09;1.20)
7.90 ×
10−9
1.16
(1.11;1.21)
2.84 × 10−10 0.003 0.00; 0.33 0 0.93 0.99
rs4944940
(rs3824999)
11q13.4
(74,415,252)
G/A 0.96 1.31
(1.24;1.39)
1.05 ×
10−20
1.28
(1.21;1.35)
3.21 × 10−17 2.73 ×
10−9
0.00; 0.19 6 0.38 0.95
rs12818766
(rs3217810)
12p13.32
(4,376,091)
A/G 0.18 1.10
(1.07;1.13)
2.15 ×
10−9
1.10
(1.07;1.13)
5.29 × 10−9 0.037 0.00; 0.06 30 0.16 0.89
rs1570405a
(rs4444235)
14q22.2
(54,554,234)
G/A 0.31 1.06
(1.03;1.08)
9.81 ×
10−7
1.07
(1.04;1.09)
1.91 × 10−8 0.125 0.02; 0.19 0 0.46 1.00
rs16969681b
(rs73376930)
15q13.3
(32,993,111)
T/C 0.09 1.22
(1.18;1.27)
2.97 ×
10−27
1.21
(1.16;1.25)
2.85 × 10−24 1.33 ×
10−16
0.01; 0.32 42 0.04 0.99
rs16959063
(rs73376930)
15q13.3
(33,105,730)
A/G 0.01 1.30
(1.18;1.42)
3.72 ×
10−8
1.33
(1.21;1.45)
5.40 × 10−9 0.23 0.00; 0.40 30 0.13 0.96
rs17816465
(rs73376930)
15q13.3
(33,156,386)
A/G 0.20 1.11
(1.08;1.14)
1.12 ×
10−14
1.12
(1.09;1.15)
8.36 × 10−15 1.07 ×
10−7
0.00; 0.11 44 0.04 0.97
rs899244
(rs2696839)
16q24.1
(86,700,030)
T/C 0.21 1.09
(1.06;1.12)
1.11 ×
10−10
1.09
(1.06;1.12)
1.13 × 10−10 4.06 ×
10−3
0.00; 0.04 14 0.29 0.99
rs6085661c
(rs961253)
20p12.3
(6,693,128)
T/C 0.39 1.09
(1.06;1.11)
1.63 ×
10−14
1.09
(1.07;1.11)
2.95 × 10−15 3.88 ×
10−8
0.00; 0.08 0 0.96 1.00
rs4811050
(rs1810502)
20q13.13
(48,980,670)
A/G 0.18 1.10
(1.07;1.13)
2.43 ×
10−11
1.09
(1.06;1.12)
4.07 × 10−9 4.06 ×
10−3
0.04; 0.45 20 0.23 0.99
rs6091213
(rs1810502)
20q13.13
(49,384,745)
C/T 0.26 1.08
(1.05;1.11)
4.35 ×
10−10
1.08
(1.05;1.11)
5.68 × 10−10 4.76 ×
10−3
0.00; 0.05 6 0.39 0.94
BFDP calculated using prior= 10−5 and maximum relative risk= 1.2. LD calculated based on European populations in the 1000 Genomes Project data. BFDP calculated using conditional analysis results,
with prior= 10−5 and maximum relative risk= 1.2
RAF risk allele frequency, OR odds ratio, CI conﬁdence interval, BFDP Bayesian False Discovery Probability, I2 proportion of the total variation due to heterogeneity, PhetP-value for heterogeneity
aTags to rs1957636 (r2= 0.67, D′= 1). Previously identiﬁed in Tomlinson IP, Nat Genet, 2008 (PMID:18372905)
bPreviously identiﬁed in Tomlinson IP, Nat Genet, 2008 (PMID:18372905)
cTags to rs4813802 (r2= 0.75, D′= 0.93). Previously identiﬁed in Tomlinson IP, Nat Genet, 2008 (PMID:18372905)
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Fig. 3 Regional plots of exemplar colorectal cancer risk loci. In the main panel, −log10P-values (y-axis) of the SNPs are shown according to their
chromosomal positions (x-axis). The colour intensity of each symbol reﬂects the extent of LD with the top SNP: white (r2= 0) through to dark red (r2=
1.0), with r2 estimated from EUR 1000 Genomes data. Genetic recombination rates (cM/Mb) are shown with a light blue line. Physical positions are based
on GRCh37 of the human genome. Where available, the upper panel shows Hi-C contacts from HT29 or LoVo. The lower panel shows the chromatin state
segmentation track from the Roadmap Epigenomics project (colonic mucosa, rectal mucosa, sigmoid colon), and HCT116. Also shown are the relative
positions of genes and transcripts mapping to each region of association. a rs12255141 (10q25.2); b rs12979278 (19q13); c rs2735940 (5p15); d rs7398375
(12q13.3)
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Project with an additional population matched reference panel: 3882 Sequencing
Initiative Suomi (SISu) haplotypes for the FIN study, and 3000 sequenced CRC
cases for the DACHS study. We imposed predeﬁned thresholds for imputation
quality to retain potential risk variants with MAF >0.5% for validation. Poorly
imputed SNPs deﬁned by an information measure <0.80 were excluded. Tests of
association between imputed SNPs and CRC were performed under an additive
genetic model in SNPTEST v2.5.260. Principal components were added to adjust
for population stratiﬁcation where required (i.e. DACHS, FIN, NSCCG-OncoAr-
ray, SCOT and UKBB).
To determine whether speciﬁc coding variants within HLA genes contributed to
the diverse association signals, we imputed the classical HLA alleles (A, B, C,
DQA1, DQB1 and DRB1) and coding variants across the HLA region using
SNP2HLA11. The imputation was based on a reference panel from the Type 1
Diabetes Genetics Consortium (T1DGC) consisting of genotype data from 5225
individuals of European descent with genotyping data of 8961 common SNPs and
indel polymorphisms across the HLA region, and four digit genotyping data of the
HLA class I and II molecules. For the X chromosome, genotypes were phased and
imputed as for the autosomal chromosome, with the inclusion of the “chrX” ﬂag. X
chromosome association analysis was performed in SNPTEST using a maximum
likelihood model, assuming complete inactivation of one allele in females and equal
effect-size between males and females.
The adequacy of the case-control matching and possibility of differential
genotyping of cases and controls was evaluated using a Q–Q plot of test statistics in
individual studies (Supplementary Figure 1). Meta-analyses were performed using
the ﬁxed-effects inverse-variance method using META v1.761. Cochran’s Q-statistic
to test for heterogeneity and the I2 statistic to quantify the proportion of the total
variation due to heterogeneity were calculated. A Q–Q plot of the meta-analysis
test statistics was also performed (Supplementary Figure 1). None of the studies
showed evidence of genomic inﬂation, where λGC values for the CCFR1, CCFR2,
COIN, CORSA, Croatia, DACHS, FIN, NSCCG-OncoArray, SCOT, Scotland1,
SOCCS/GS, SOCCS/LBC, UKBB, UK1 and VQ58 studies were 1.03, 1.08, 1.09,
1.11, 1.01, 1.01, 1.09, 1.10, 1.08, 1.02, 1.09, 1.04, 1.05, 1.02 and 1.06, respectively.
Estimates were calculated using the regression method, as implemented in
GenABEL.
Deﬁnition of known and new risk loci. We sought to identify all associations for
CRC previously reported at a signiﬁcance level P < 5 × 10−8 by referencing the
NHGRI-EBI Catalog of published genome-wide association studies, and a literature
search for the years 1998–2018 using PubMed (performed January 2018). Addi-
tional articles were ascertained through references cited in primary publications.
Where multiple studies reported associations in the same region, we only con-
sidered the ﬁrst reported genome-wide signiﬁcant association. New loci were
identiﬁed based on SNPs at P < 5 × 10−8 using the meta-analysis summary statis-
tics, with LD correlations from a reference panel of the European 1000 Genomes
Project samples combined with UK10K. We only included one SNP per 500 kb
interval. To measure the probability of the hits being false positives, the Bayesian
False-Discovery Probability (BFDP)9 was calculated based on a plausible OR of 1.2
(based on the 95th percentile of the meta-analysis OR values) and a prior prob-
ability of association of 10−5. A conditional analysis was performed using Genome-
wide Complex Trait Analysis (GCTA)62, conditioning on the new and known
SNPs, and SNPs with Pconditioned < 5 × 10−8 and r2 > 0.1 were clumped using
PLINK. The NSCCG-Oncoarray data were used to provide the LD reference data.
Fidelity of imputation. The reliability of imputation of the novel risk SNPs
identiﬁed (all with an IMPUTE2 r2 > 0.8) was assessed for 51 SNPs (comprising all
new signals not directly genotyped) by examining the concordance between
imputed and whole-genome sequenced genotypes in a subset of 201 samples from
the CORGI and NSCCG studies. More than 98% concordance was found between
the directly sequenced and imputed SNPs (Supplementary Data 14).
eQTL analysis. In the INTERMPHEN study, biopsies of normal colorectal mucosa
(trios of rectum, proximal colon and distal colon) were obtained from 131 UK
individuals with self-reported European ancestry without CRC. Genotyping was
performed using the Illumina Inﬁnium Human Core Exome array, with quality
control and imputation as above. RNA-seq was performed and data analysed as per
the GTEx Project pipeline v7 using the 1000 Genomes and UK10K data as
reference. Gene-level expression quantiﬁcation was based on the GENCODE 19
annotation, collapsed to a single transcript model for each gene using a custom
isoform procedure. Gene-level quantiﬁcation (read counts and TPM values) was
performed with RNA-SeQC v1.1.8. Gene expression was normalised using the
TMM algorithm, implemented in edgeR, with inverse normal transformation,
based on gene expression thresholds of >0.1 Transcripts Per Million (TPM) in
≥20% of samples and ≥6 reads in ≥20% of samples. cis-eQTL mapping was per-
formed separately for proximal colon, distal colon and rectum samples using
FastQTL. Principal components for the SNP data and additional covariate factors
were identiﬁed using Probabilistic Estimation of Expression Residuals (PEER).
P-values were generated for each variant-gene pair testing alternative hypothesis
that the slope of a linear regression model between genotype and expression
deviates from 0. The mapping window was deﬁned as 1Mb either side of the
transcription start site. Beta distribution-adjusted empirical P-values from FastQTL
were used to calculate Q-values, and FDR threshold of ≤0.05 was applied to identify
genes with a signiﬁcant eQTL. The normalised effect size of the eQTLs was deﬁned
as the slope of the linear regression, and computed as the effect of the alternative
allele relative to the reference allele in the human genome reference GRCh37/
hg19). MetaTissue was used to generate a “pan-colonic” eQTL measure from the
three individual RNA-seq datasets per patient.
To supplement this analysis, we performed SMR analysis28 including all eQTLs
with nominally signiﬁcant associations (P < 0.05). We additionally examined for
heterogeneity using the heterogeneity in dependent instruments (HEIDI) test,
where PHEIDI < 0.05 were considered as reﬂective of heterogeneity and were
excluded.
Promoter capture Hi-C. In situ promoter capture Hi-C (CHi-C) on LoVo and
HT29 cell lines was performed as previously described63. Hi-C and CHi-C libraries
were sequenced using HiSeq 2000 (Illumina). Reads were aligned to the GRCh37
build using bowtie2 v2.2.6 and identiﬁcation of valid di-tags was performed using
HiCUP v0.5.9. To declare signiﬁcant contacts, HiCUP output was processed using
CHiCAGO v1.1.8. For each cell line, data from three independent biological
replicates were combined to obtain a deﬁnitive set of contacts. As advocated,
interactions with a score ≥5.0 were considered to be statistically signiﬁcant64.
Chromatin state annotation. Colorectal cancer risk loci and SNPs in LD (r2 > 0.8)
were annotated for putative functional effect based upon ChIP-seq H3K4me1
(C15410194), H3K9me3 (C15410193), H3K27me3 (C15410195) and H3K36me3
(C15410192) for LoVo, and H3K4me1 and H3K9me3 for HT29. ChIP libraries
were sequenced using HiSeq 2000 (Illumina) with 100 bp single-ended reads.
Generated raw reads were ﬁltered for quality (Phred33 ≥ 30) and length (n ≥ 32),
and adapter sequences were removed using Trimmomatic v0.22. Reads passing
ﬁlters were then aligned to the human reference (hg19) using BWA v0.6.1. Peak
calls are obtained using MACS2 v 2.0.10.07132012.
Histone mark and transcription factor enrichment analysis. ChIP-seq data from
colon crypt and tumour samples was obtained for H3K27ac and H3K4me165.
Multiple samples of the same tissue type or tumour stage were merged together.
Additional ChIP-seq data from the Roadmap Epigenomics project21 was obtained
for H3K4me3, H3K27ac, H3K4me1, H3K27me3, H3K9ac, H3K9me3 and
H3K36me3 marks in up to 114 tissues. Overlap enrichment analysis of CRC risk
SNPs with these peaks was performed using EPIGWAS, as described by Trynka
et al.20. Brieﬂy, we evaluated if CRC risk SNPs and SNPs in LD (r2 > 0.8) with the
sentinel SNP, were enriched at ChIP-seq peaks in tissues by a permutation pro-
cedure with 105 iterations.
To examine enrichment in speciﬁc TF binding across risk loci, we adapted the
variant set enrichment method of Cowper-Sal lari et al.22. Brieﬂy, for each risk locus, a
region of strong LD (deﬁned as r2 > 0.8 and D′ > 0.8) was determined, and these SNPs
were termed the associated variant set (AVS). ChIP-seq uniform peak data were
obtained for LoVo and HT29 cell lines (198 and 29 experiments, respectively)66 and the
above described histone marks. For each of these marks, the overlap of the SNPs in the
AVS and the binding sites was determined to produce a mapping tally. A null
distribution was produced by randomly selecting SNPs with the same characteristics as
the risk-associated SNPs, and the null mapping tally calculated. This process was
repeated 105 times, and P-values calculated as the proportion of permutations where the
null mapping tally was greater or equal to the AVS mapping tally. An enrichment score
was calculated by normalising the tallies to the median of the null distribution. Thus, the
enrichment score is the number of standard deviations of the AVS mapping tally from
the median of the null distribution tallies.
Functional annotation. For the integrated functional annotation of risk loci, LD
blocks were deﬁned as all SNPs in r2 > 0.8 with the sentinel SNP. Risk loci were
then annotated with ﬁve types of functional data: (i) presence of a CHi-C contact
linking to a gene promoter, (ii) presence of an association from eQTL, (iii) presence
of a regulatory state, (iv) evidence of TF binding, and (v) presence of a non-
synonymous coding change. Candidate causal genes were then assigned to CRC
risk loci using the target genes implicated in annotation tracks (i), (ii), (iiii) and
(iv). If the data supported multiple gene candidates, the gene with the highest
number of individual functional data points was considered as the candidate.
Where multiple genes had the same number of data points, all genes were listed.
Direct nonsynonymous coding variants were allocated additional weighting.
Competing mechanisms for the same gene (e.g. both coding and promoter var-
iants) were allowed for. Finally, if no evidence was provided by these criteria, if the
lead SNP was intronic we assigned candidacy on this basis, or if intergenic the
nearest gene neighbour. Chromatin data were obtained from HaploReg v4 and
regulatory regions from Ensembl.
Regional plots were created using visPIG67, using the data described above. We
used ChromHMM to integrate DNAse, H3K4me3, H3K4me1, H3K27ac, Pol2 and
CTCF states from the CRC cell line HCT116 using a multivariate Hidden Markov
Model68. Chromatin annotation tracks for colonic mucosa (E075), rectal mucosa
(E101) and sigmoid colon (E106) were obtained from the Roadmap Epigenomics
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project21, using the core 15-state model data based on H3K4me3, H3K4me1,
H3K36me3, H3K27me3 and H3K9me3 marks.
Transcription factor binding disruption analysis. To determine if the risk variants
or their proxies were disrupting motif binding sites, we used the motifbreakR package69.
This tool predicts the effects of variants on TF binding motifs, using position probability
matrices to determine the likelihood of observing a particular nucleotide at a speciﬁc
position within a TF binding site. We tested the SNPs by estimating their effects on over
2,800 binding motifs as characterised by ENCODE, FactorBook, HOCOMOCO and
HOMER. Scores were calculated using the relative entropy algorithm.
Heritability analysis. We used LDAK35 to estimate the polygenic variance (i.e.
heritability) ascribable to SNPs from summary statistic data for the GWAS datasets
which were based on unselected cases (i.e. CORSA, COIN, Croatia, DACHS, FIN,
SCOT, Scotland1, SOCCS/GS, SOCCS/LBC, UKBB and VQ58). SNP-speciﬁc expected
heritability, adjusted for LD, MAF and genotype certainty, was calculated from the
UK10K and 1000 Genomes data. Individuals were excluded if they were closely related,
had divergent ancestry from CEU, or had a call rate <0.99. SNPs were excluded if they
showed deviation from HWE with P < 1 × 10−5, genotype yield <95%, MAF <1%, SNP
imputation score <0.99, and the absence of the SNP in the GWAS summary statistic
data. This resulted in a total 6,024,731 SNPs used to estimate the heritability of CRC.
To estimate the sample size required to detect a given proportion of the GWAS
heritability we implemented a likelihood-based approach to model the effect-size
distribution36, using association statistics from the meta-analysis, and LD
information from individuals of European ancestry in the 1000 Genomes Project
Phase 3. LD values were based on an r2 threshold of 0.1 and a window size of 1MB.
The goodness of ﬁt of the observed distribution of P-values against the expected
from a two-component model (single normal distribution) and a three-component
model (mixture of two normal distributions) were assessed, and a better ﬁt was
observed for the latter model. The percentage of GWAS heritability explained for a
projected sample size was determined using this model, based on power
calculations for the discovery of genome-wide signiﬁcant SNPs. The genetic
variance explained was calculated as the proportion of total GWAS heritability
explained by SNPs reaching genome-wide signiﬁcance at a given sample size. The
95% conﬁdence intervals were determined using 105 simulations.
Cross-trait genetic correlation. LD score regression39 was used to determine if
any traits were correlated with CRC risk. GWAS summary data were obtained for
allergy, asthma, coronary artery disease, fatty acids, lipids (total cholesterol, high
density lipoprotein, low-density lipoprotein, triglycerides), auto-immune diseases
(Crohn’s disease, rheumatoid arthritis, atopic dermatitis, celiac disease, multiple
sclerosis, primary biliary cirrhosis, inﬂammatory bowel disease, ulcerative colitis,
systemic lupus erythematosus), anthropometric measures (BMI, height, body fat),
glucose sensitivity (fasting glucose, fasting insulin, HbA1c), childhood measures
(birth weight, birth length, childhood obesity, childhood BMI), eGFR and type 2
diabetes. All data were obtained for European populations. Summary statistics were
reformatted to be consistent, and constrained to HapMap3 SNPs as these have
been found to generally impute well. LD Scores were determined using 1000
Genomes European data.
Familial risk explained by risk SNPs. Under a multiplicative model, the contribu-
tion of risk SNPs to the familial risk of CRC was calculated from
P
k
logλk
log λ0
, where λ0 is the
familial risk to ﬁrst-degree relatives of CRC cases, assumed to be 2.238, and λk is the
familial relative risk associated with SNP k, calculated as λk ¼ pkr
2
kþqk
pkrkþqkð Þ2
, where pk is the
risk allele frequency for SNP k, qk= 1−pk, and rk is the estimated per-allele OR from the
meta-analysis70. The OR estimates were adjusted for the winner’s curse using the FDR
Inverse Quantile Transformation (FIQT) method37. We constructed a PRS including all
79 CRC risk SNPs discovered or validated by this GWAS in the risk-score modelling.
The distribution of risk on an RR scale in the population is assumed to be log-normal
with arbitrary population mean μ set to -σ2/2 and variance σ2 ¼ 2P
k
pkð1 pkÞβ2
where β and p correspond to the log odds ratio and the risk allele frequency, respec-
tively, for SNP k. The distribution of PRS among cases is right-shifted by σ2 so that the
overall mean PRS is 1.071. The risk distribution was also performed assuming all
common variation, using σ2 ¼ logðλ2sibÞ, where λsib= 1.79, as determined using the
heritability estimate from GCTA.
Pathway analysis. SNPs were assigned to genes as described in the functional
annotation section. The genes that mapped to genome-wide signiﬁcant CRC risk
SNPs were analysed using InBio Map, a manually curated database of protein-
protein interactions.
Gene set enrichment was calculated using GenGen. Enrichment scores were
calculated using the meta-analysis results and were based on 103 permutations on
the χ2 values between SNPs. Pathway deﬁnitions were obtained from the Bader
Lab33, University of Toronto, July 2018 release. This data contained pathway
information from Gene Ontology (GO), Reactome, HumanCyc, MSigdb C2
(curated dataset), NCI Pathway, NetPath and PANTHER for a total of 7269
pathways. GO annotations that were inferred computationally were excluded. To
avoid biasing the results, the meta-analysis SNPs were pruned to only those with an
r2 < 0.1 and a distance greater than 500 kb. Pathways were visualised using
Cytoscape v3.6.1, together with the EnrichmentMap v3.1.0 and AutoAnnotate v1.2
plugins. Only pathways with an FDR <0.05 and edges with a similarity coefﬁcient
(number of shared genes between pathways) >0.55 were displayed.
URLs. Bader Lab pathway data: http://download.baderlab.org/EM_Genesets/
July_01_2018/Human/symbol/
FastQTL: https://github.com/francois-a/fastqtl
GTEx: https://www.gtexportal.org/home/
InBioMap: https://www.intomics.com/inbio/map/#home
LD scores: https://data.broadinstitute.org/alkesgroup/LDSCORE/
NHGRI-EBI GWAS Catalog: https://www.ebi.ac.uk/gwas/
PredictDB: http://predictdb.org/
Roadmap Epigenomics data: https://egg2.wustl.edu/roadmap/web_portal/
chr_state_learning.html
SYSCOL: http://syscol-project.eu/
UK Biobank: http://www.ukbiobank.ac.uk/scientists-3/genetic-data/
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The SCOT data can be requested through the TransSCOT committee according to the
ethical permissions obtained as part of the clinical trial approval. The PRACTICAL and
BCAC consortium control data are available through the respective Data Access
Coordination Committees (http://practical.icr.ac.uk and http://bcac.ccge.medschl.cam.ac.
uk/) and the Heinz Nixdorf Recall Study control data can be requested through https://
www.uni-due.de/recall-studie/die-studien/hnr/. UK Biobank data can be obtained
through http://www.ukbiobank.ac.uk/. The Colon Cancer Family Registry data can be
obtained through http://coloncfr.org/.
Finnish cohort samples can be requested from THL Biobank https://thl.ﬁ/en/web/thl-
biobank. Hi-C, CHi-C, and histone ChIPseq sequencing data have been deposited in the
European Genome-phenome Archive (EGA) under the accession code EGAS00001001946.
The remaining data are contained within the Supplementary Files or available from the
authors upon reasonable request.
Code availability
All bioinformatics and statistical analysis tools used are open source.
Received: 31 October 2018 Accepted: 29 March 2019
References
1. Graff, R. E. et al. Familial risk and heritability of colorectal cancer in the
nordic twin study of cancer. Clin. Gastroenterol. Hepatol. 15, 1256–1264
(2017).
2. Schmit, S. L. et al. Novel common genetic susceptibility loci for colorectal
cancer. J. Natl. Cancer Inst. 111, 146–157 (2018).
3. Orlando, G. et al. Variation at 2q35 (PNKD and TMBIM1) inﬂuences
colorectal cancer risk and identiﬁes a pleiotropic effect with inﬂammatory
bowel disease. Hum. Mol. Genet 25, 2349–2359 (2016).
4. Tanikawa, C. et al. GWAS identiﬁes two novel colorectal cancer loci at 16q24.1
and 20q13.12. Carcinogenesis 39, 652–660 (2018).
5. Zeng, C. et al. Identiﬁcation of susceptibility loci and genes for colorectal
cancer risk. Gastroenterology 150, 1633–1645 (2016).
6. Frampton, M. J. et al. Implications of polygenic risk for personalised colorectal
cancer screening. Ann. Oncol. 27, 429–434 (2016).
7. Tomlinson, I. P. et al. COGENT (COlorectal cancer GENeTics): an
international consortium to study the role of polymorphic variation on the
risk of colorectal cancer. Br. J. Cancer 102, 447–454 (2010).
8. Anderson, C. A. et al. Data quality control in genetic case-control association
studies. Nat. Protoc. 5, 1564–1573 (2010).
9. Wakeﬁeld, J. A Bayesian measure of the probability of false discovery in
genetic epidemiology studies. Am. J. Hum. Genet 81, 208–227 (2007).
10. Schumacher, F. R. et al. Genome-wide association study of colorectal cancer
identiﬁes six new susceptibility loci. Nat. Commun. 6, 7138 (2015).
11. Jia, X. et al. Imputing amino acid polymorphisms in human leukocyte
antigens. PLoS ONE 8, e64683 (2013).
12. Houlston, R. S. et al. Meta-analysis of three genome-wide association studies
identiﬁes susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and
20q13.33. Nat. Genet. 42, 973–977 (2010).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w
10 NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications
13. Cogent Study et al. Meta-analysis of genome-wide association data identiﬁes four
new susceptibility loci for colorectal cancer. Nat. Genet. 40, 1426–1435 (2008).
14. Whifﬁn, N. et al. Identiﬁcation of susceptibility loci for colorectal cancer in a
genome-wide meta-analysis. Hum. Mol. Genet. 23, 4729–4737 (2014).
15. Peters, U. et al. Meta-analysis of new genome-wide association studies of
colorectal cancer risk. Hum. Genet. 131, 217–234 (2012).
16. Real, L. M. et al. A colorectal cancer susceptibility new variant at 4q26 in the
Spanish population identiﬁed by genome-wide association analysis. PLoS ONE
9, e101178 (2014).
17. Schmit, S. L. et al. A novel colorectal cancer risk locus at 4q32.2 identiﬁed
from an international genome-wide association study. Carcinogenesis 35,
2512–2519 (2014).
18. Tomlinson, I. P. et al. Multiple common susceptibility variants near BMP
pathway loci GREM1, BMP4, and BMP2 explain part of the missing
heritability of colorectal cancer. PLoS Genet. 7, e1002105 (2011).
19. Sud, A., Kinnersley, B. & Houlston, R. S. Genome-wide association studies of
cancer: current insights and future perspectives. Nat. Rev. Cancer 17, 692–704
(2017).
20. Trynka, G. et al. Chromatin marks identify critical cell types for ﬁne mapping
complex trait variants. Nat. Genet. 45, 124–130 (2013).
21. Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference
human epigenomes. Nature 518, 317–330 (2015).
22. Cowper-Sal lari, R. et al. Breast cancer risk-associated SNPs modulate the
afﬁnity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44,
1191–1198 (2012).
23. Bienz, M. & Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 103,
311–320 (2000).
24. Tuupanen, S. et al. The common colorectal cancer predisposition SNP
rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.
Nat. Genet. 41, 885–890 (2009).
25. Lewis, A. et al. A polymorphic enhancer near GREM1 inﬂuences bowel cancer
risk through differential CDX2 and TCF7L2 binding. Cell Rep. 8, 983–990 (2014).
26. Lan, Q. et al. Genome-wide association analysis identiﬁes new lung cancer
susceptibility loci in never-smoking women in Asia. Nat. Genet. 44,
1330–1335 (2012).
27. Kinnersley, B. et al. Genome-wide association study identiﬁes multiple
susceptibility loci for glioma. Nat. Commun. 6, 8559 (2015).
28. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies
predicts complex trait gene targets. Nat. Genet. 48, 481–487 (2016).
29. Wu, S., Trievel, R. C. & Rice, J. C. Human SFMBT is a transcriptional
repressor protein that selectively binds the N-terminal tail of histone H3. FEBS
Lett. 581, 3289–3296 (2007).
30. Munoz, J. et al. The Lgr5 intestinal stem cell signature: robust expression of
proposed quiescent ‘+ 4’ cell markers. EMBO J. 31, 3079–3091 (2012).
31. Westendorf, J. J., Kahler, R. A. & Schroeder, T. M. Wnt signaling in
osteoblasts and bone diseases. Gene 341, 19–39 (2004).
32. Wacklin, P. et al. Faecal microbiota composition in adults is associated with
the FUT2 gene determining the secretor status. PLoS ONE 9, e94863 (2014).
33. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map:
a network-based method for gene-set enrichment visualization and
interpretation. PLoS ONE 5, e13984 (2010).
34. Pers, T. H. et al. Biological interpretation of genome-wide association studies
using predicted gene functions. Nat. Commun. 6, 5890 (2015).
35. Speed, D. et al. Reevaluation of SNP heritability in complex human traits. Nat.
Genet. 49, 986–992 (2017).
36. Zhang, Y., Qi, G., Park, J. H. & Chatterjee, N. Estimation of complex effect-size
distributions using summary-level statistics from genome-wide association
studies across 32 complex traits. Nat. Genet. 50, 1318–1326 (2018).
37. Bigdeli, T. B. et al. A simple yet accurate correction for winner’s curse can
predict signals discovered in much larger genome scans. Bioinformatics 32,
2598–2603 (2016).
38. Johns, L. E. & Houlston, R. S. A systematic review and meta-analysis of
familial colorectal cancer risk. Am. J. Gastroenterol. 96, 2992–3003 (2001).
39. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases
and traits. Nat. Genet. 47, 1236–1241 (2015).
40. Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in
ulcerative colitis: a meta-analysis. Gut 48, 526–535 (2001).
41. Shikata, K., Ninomiya, T. & Kiyohara, Y. Diabetes mellitus and cancer risk:
review of the epidemiological evidence. Cancer Sci. 104, 9–14 (2013).
42. Huyghe, J. R. et al. Discovery of common and rare genetic risk variants for
colorectal cancer. Nat. Genet. 51, 76–87 (2019).
43. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97,
1305–1309 (2007).
44. Paul, J. et al. SCOT: Short Course Oncology Therapy—a comparison of 12 and
24 weeks of adjuvant chemotherapy in colorectal cancer. J. Clin. Oncol. 29,
e14145–e14145 (2011).
45. Schmermund, A. et al. Assessment of clinically silent atherosclerotic disease
and established and novel risk factors for predicting myocardial infarction and
cardiac death in healthy middle-aged subjects: rationale and design of the
Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium
and Lifestyle. Am. Heart J. 144, 212–218 (2002).
46. Smith, B. H. et al. Cohort Proﬁle: Generation Scotland: Scottish Family
Health Study (GS:SFHS). The study, its participants and their potential
for genetic research on health and illness. Int J. Epidemiol. 42, 689–700
(2013).
47. Theodoratou, E. et al. Dietary vitamin B6 intake and the risk of colorectal
cancer. Cancer Epidemiol. Biomark. Prev. 17, 171–182 (2008).
48. Deary, I. J., Gow, A. J., Pattie, A. & Starr, J. M. Cohort proﬁle: the
Lothian Birth Cohorts of 1921 and 1936. Int J. Epidemiol. 41, 1576–1584
(2012).
49. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and
genomic data. Nature 562, 203–209 (2018).
50. Power, C. & Elliott, J. Cohort proﬁle: 1958 British birth cohort (National Child
Development Study). Int J. Epidemiol. 35, 34–41 (2006).
51. Hunter, D. J. et al. A genome-wide association study identiﬁes alleles in
FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat.
Genet 39, 870–874 (2007).
52. Yeager, M. et al. Genome-wide association study of prostate cancer identiﬁes a
second risk locus at 8q24. Nat. Genet. 39, 645–649 (2007).
53. Al-Tassan, N. A. et al. A new GWAS and meta-analysis with 1000Genomes
imputation identiﬁes novel risk variants for colorectal cancer. Sci. Rep. 5,
10442 (2015).
54. Hofer, P. et al. Bayesian and frequentist analysis of an Austrian genome-wide
association study of colorectal cancer and advanced adenomas. Oncotarget 8,
98623–98634 (2017).
55. Weigl, K. et al. Strongly enhanced colorectal cancer risk stratiﬁcation by
combining family history and genetic risk score. Clin. Epidemiol. 10, 143–152
(2018).
56. He, Y. et al. Exploring causality in the association between circulating 25-
hydroxyvitamin D and colorectal cancer risk: a large Mendelian
randomisation study. BMC Med. 16, 142 (2018).
57. Purcell, S. et al. PLINK: a tool set for whole-genome association and
population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575
(2007).
58. Delaneau, O., Marchini, J. & Zagury, J. F. A linear complexity phasing method
for thousands of genomes. Nat. Methods 9, 179–181 (2011).
59. Howie, B. N., Donnelly, P. & Marchini, J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet. 5, e1000529 (2009).
60. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new
multipoint method for genome-wide association studies by imputation of
genotypes. Nat. Genet. 39, 906–913 (2007).
61. Liu, J. Z. et al. Meta-analysis and imputation reﬁnes the association of 15q25
with smoking quantity. Nat. Genet. 42, 436–440 (2010).
62. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for
genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
63. Orlando, G., Kinnersley, B. & Houlston, R. S. Capture Hi-C library generation
and analysis to detect chromatin interactions. Curr. Protoc. Hum. Genet. 98,
e63 (2018).
64. Cairns, J. et al. CHiCAGO: robust detection of DNA looping interactions in
Capture Hi-C data. . Genome Biol. 17, 127 (2016).
65. Cohen, A. J. et al. Hotspots of aberrant enhancer activity punctuate the
colorectal cancer epigenome. Nat. Commun. 8, 14400 (2017).
66. Yan, J. et al. Transcription factor binding in human cells occurs in dense
clusters formed around cohesin anchor sites. Cell 154, 801–813 (2013).
67. Scales, M., Jager, R., Migliorini, G., Houlston, R. S. & Henrion, M. Y. visPIG--a
web tool for producing multi-region, multi-track, multi-scale plots of genetic
data. PLoS ONE 9, e107497 (2014).
68. Jager, R. et al. Capture Hi-C identiﬁes the chromatin interactome of colorectal
cancer risk loci. Nat. Commun. 6, 6178 (2015).
69. Coetzee, S. G., Coetzee, G. A. & Hazelett, D. J. motifbreakR: an R/
Bioconductor package for predicting variant effects at transcription factor
binding sites. Bioinformatics 31, 3847–3849 (2015).
70. Schumacher, F. R. et al. Association analyses of more than 140,000 men
identify 63 new prostate cancer susceptibility loci. Nat. Genet. 50, 928–936
(2018).
71. Pharoah, P. D., Antoniou, A. C., Easton, D. F. & Ponder, B. A. Polygenes, risk
prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358,
2796–2803 (2008).
Acknowledgements
At the Institute of Cancer Research, this work was supported by Cancer Research UK
(C1298/A25514). Additional support was provided by the National Cancer Research
Network. In Edinburgh, the work was supported by Programme Grant funding from
Cancer Research UK (C348/A12076) and by funding for the infrastructure and stafﬁng of
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications 11
the Edinburgh CRUK Cancer Research Centre. In Birmingham, funding was provided by
Cancer Research UK (C6199/A16459). We are grateful to many colleagues within UK
Clinical Genetics Departments (for CORGI) and to many collaborators who participated
in the VICTOR, QUASAR2 and SCOT trials.
We also thank colleagues from the UK National Cancer Research Network (for
NSCCG). Support from the European Union [FP7/207–2013, grant 258236] and FP7
collaborative project SYSCOL and COST Action in the UK is also acknowledged
[BM1206]. The COIN and COIN-B trials were funded by Cancer Research UK and the
Medical Research Council and were conducted with the support of the National Institute
of Health Research Cancer Research Network. COIN and COIN-B translational studies
were supported by the Bobby Moore Fund from Cancer Research UK, Tenovus, the
Kidani Trust, Cancer Research Wales and the National Institute for Social Care and
Health Research Cancer Genetics Biomedical Research Unit (2011–2014).
We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for
Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z) and the
Edinburgh Clinical Research Facility (ECRF) Genetics Core, Western General Hospital,
Edinburgh, for the generation of genotyping data.
We thank the Lothian Birth Cohorts’ members, investigators, research associates, and
other team members. We thank the Edinburgh Clinical Research Facility (ECRF)
Genetics Core, Western General Hospital, Edinburgh, for genotyping. Lothian Birth
Cohorts’ data collection is supported by the Disconnected Mind project (funded by Age
UK), and the Biotechnology and Biological Sciences Research Council (BBSRC, for
genotyping; BB/F019394/1) and undertaken within the University of Edinburgh Centre
for Cognitive Ageing and Cognitive Epidemiology (funded by the BBSRC and Medical
Research Council RC as part of the LLHW [MR/K026992/1]). ET was supported by
Cancer Research UK CDF (C31250/A22804). This research has been conducted using the
UK Biobank Resource under Application Number 7441.
Generation Scotland received core support from the Chief Scientist Ofﬁce of the Scottish
Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006].
Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the
Clinical Research Facility, University of Edinburgh and was funded by the Medical Research
Council UK and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resi-
lience and Depression Longitudinally” (STRADL) [104036/Z/14/Z]).
CFR was supported by a Marie Sklodowska-Curie Intra-European Fellowship Action
and received considerable help from many staff in the Department of Endoscopy at the
John Radcliffe Hospital in Oxford.
In Finland, this work was supported by grants from the Academy of Finland [Finnish
Center of Excellence Program 2012–2017, 250345 and 2018–2025, 312041], the Jane and
Aatos Erkko Foundation, the Finnish Cancer Society [personal grant to K.P.], the Eur-
opean Research Council [ERC; 268648], the Sigrid Juselius Foundation, SYSCOL, the
Nordic Information for Action eScience Center (NIASC), the Nordic Center of Excel-
lence ﬁnanced by NordForsk [project 62721, personal grant to K.P.] and State Research
Funding of Kuopio University Hospital [B1401]. We acknowledge the computational
resources provided by the ELIXIR node, hosted at the CSC–IT Center for Science,
Finland, and funded by the Academy of Finland [grants 271642 and 263164], the
Ministry of Education and Culture, Finland. V.S. was supported by the Finnish Academy
[grant number 139635] and the Finnish Foundation for Cardiovascular Research. J.-P.M.
was funded by The Finnish Cancer Foundation and The Jane and Aatos Erkko Foun-
dation. Sample collection and genotyping in the Finnish Twin Cohort has been sup-
ported by the Wellcome Trust Sanger Institute, ENGAGE—European Network for
Genetic and Genomic Epidemiology, FP7-HEALTH-F4–2007; [grant agreement number
201413], the National Institute of Alcohol Abuse and Alcoholism [grants AA-12502 and
AA-00145; to R.J.R. and K02AA018755 to D.M.D.] and the Academy of Finland [grants
100499, 205585, 265240 and 263278 to J.K.].
The work of the Colon Cancer Family Registry (CCFR) was supported by the National
Cancer Institute (NCI) of the National Institutes of Health (NIH) under Award number
U01 CA167551. The CCFR Illumina GWAS was supported by the NCI/NIH under
Award Numbers U01 CA122839 and R01 CA143237 to G.C. The content of this
manuscript does not necessarily reﬂect the views or policies of the NCI or any of the
collaborating centres in the CCFR, nor does mention of trade names, commercial pro-
ducts, or organizations imply endorsement by the US Government or the CCFR.
The CORSA study was funded by FFG BRIDGE (grant 829675, to A.G.), the “Herz-
felder’sche Familienstiftung” (grant to A.G.) and was supported by COST Action
BM1206. We kindly thank all individuals who agreed to participate in the CORSA study.
Furthermore, we thank all cooperating physicians and students and the Biobank Graz of
the Medical University of Graz.
The DACHS study was supported by grants from the German Research Council
(Deutsche Forschungsgemeinschaft, BR 1704/6–1, BR 1704/6–3, BR 1704/6–4, BR 1704/
6–6 and CH 117/1–1), and the German Federal Ministry of Education and Research
(01KH0404, 01ER0814, 01ER0815 and 01ER1505A, 01ER1505B). We thank all partici-
pants and cooperating clinicians, and Ute Handte-Daub, Ansgar Brandhorst, Muhabbet
Celik and Ursula Eilber for excellent technical assistance.
The Croatian study was supported through the 10,001 Dalmatians Project, and
institutional support of University Hospital for Tumours, Sestre milosrdnice University
Hospital Center.
James East and Simon Leedham were funded by the National Institute for Health
Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed not
necessarily those of the NHS, the NIHR or the Department of Health.
We acknowledge use of genotype data from the British 1958 Birth Cohort DNA
collection, which was funded by the Medical Research Council Grant G0000934 and the
Wellcome Trust Grant 068545/Z/02. A full list of the investigators who contributed to
the generation of the data is available from http://www.wtccc.org.uk.
The BCAC study would not have been possible without the contributions of the
following: Manjeet K. Bolla, Qin Wang, Kyriaki Michailidou and Joe Dennis. BCAC is
funded by Cancer Research UK (C1287/A10118, C1287/A16563). For the BBCS study,
we thank Eileen Williams, Elaine Ryder-Mills, Kara Sargus. The BBCS is funded by
Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the
National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) and
the National Cancer Research Network (NCRN). We thank the participants and the
investigators of EPIC (European Prospective Investigation into Cancer and Nutrition).
The coordination of EPIC is ﬁnancially supported by the European Commission (DG-
SANCO) and the International Agency for Research on Cancer. The national cohorts
are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale
de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale
(INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ),
Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health
Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la
Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry
of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK
Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland),
World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands);
Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia,
Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra,
ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk;
C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council
(1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom).
We thank the SEARCH and EPIC teams, which were funded by a programme
grant from Cancer Research UK (C490/A10124) and supported by the UK NIHR
BRC at the University of Cambridge. We thank Breast Cancer Now and the Institute
of Cancer Research (ICR) for support and funding of the UKBGS, and the study
participants, study staff, and the doctors, nurses and other health-care providers
and health information sources who have contributed to the study.
Genotyping of the PRACTICAL consortium OncoArray was funded by the US
National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved
in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center
for Inherited Disease Research (CIDR) under contract number
HHSN268201200008I]. Additional analytic support was provided by NIH NCI U01
CA188392 (PI: Schumacher). The PRACTICAL consortium was supported by Cancer
Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354,
C5047/A10692, C16913/A6135, European Commission’s Seventh Framework Pro-
gramme grant agreement n° 223175 (HEALTH-F2–2009–223175), and The National
Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA
148537–01 (the GAME-ON initiative). We would also like to thank the following for
funding support: The Institute of Cancer Research and The Everyman Campaign, The
Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Pros-
tate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK,
The National Cancer Research Institute (NCRI) UK. We are grateful for support of
NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust, the Spanish Instituto de
Salud Carlos III (ISCIII) an initiative of the Spanish Ministry of Economy and
Innovation (Spain), and the Xunta de Galicia (Spain).
The APBC BioResource, which forms part of the PRACTICAL consortium, consists of
the following members: Wayne Tilley, Gail Risbridger, Renea Taylor, Lisa Horvath, Vanessa
Hayes, Lisa Butler, Trina Yeadon, Allison Eckert, Anne-Maree Haynes, Melissa Papargiris.
We are grateful for the provision of public data from the GTEx consortium.
Finally, the authors gratefully acknowledge the participation of patients, their families,
and controls in the relevant studies.
Author contributions
Study concept and design: R.S.H., I.T. and M.G.D. Patient recruitment: S.P. and L.M.
Sample preparation and genotyping: A.Holroyd., P.B. Primary data analysis: P.J.L., M.T.,
C.F.-R. and J.F.-T. Additional analysis: J.Studd., G.O., A.Sud., S.F., V.S., C.P., S.Briggs.,
L.M., E.Jaeger., A.S.-O., J.E. and S.L. Provided sample data: E.T., P.V.-S., L.Z., A.C., H.C.,
C.H., S.H., I.J.D., J.Starr., R.A., E.Johnstone., H.W., L.G., M.P., D.K., R.Kerr., T.M.,
R.Kaplan., N.A.-T., J.P.C., K.P., L.A.A., U.A.H., T.C., T.T., J.K., E.K., A.-P.S., J.G.E., H.R.,
P.K., E.P., P.J., V.S., S.R., A.P., L.R.-S., A.L., J.B., J.-P.M., D.D.B., A.-K.W., J.H., M.E.J.,
N.M.L., P.A.N., S.G., D.D., G.C., P.Hoffmann., M.M.N., K.-H.J., D.F.E., P.D.P.P., J.Peto.,
F.C., A.Swerdlow., R.A.E., Z.K.-J., K.M., N.P., PRACTICAL Consortium, A.Harkin., K.A.,
J.M., J.Paul., T.I., M.S., K.B., J.C.-C., M.H., H.B., I.K., P.M., P.Hofer., S.Brezina. and A.G.
Writing manuscript: R.S.H., I.T., M.G.D and P.J.L. All authors read and approved the
ﬁnal version of the manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
019-09775-w.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w
12 NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications
Competing interests: D.K. is a founder and shareholder of Oxford Cancer Biomarkers.
V.S. has participated in a conference trip sponsored by Novo Nordisk and received an
honorarium from the same source for participating in an advisory board meeting. The
remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Journal peer review information: Nature Communications thanks the anonymous
reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports
are available.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2019
Philip J. Law 1, Maria Timofeeva 2, Ceres Fernandez-Rozadilla 3,4, Peter Broderick 1, James Studd 1,
Juan Fernandez-Tajes5, Susan Farrington 2, Victoria Svinti 2, Claire Palles6, Giulia Orlando1, Amit Sud 1,
Amy Holroyd1, Steven Penegar1, Evropi Theodoratou2,7, Peter Vaughan-Shaw2, Harry Campbell2,7, Lina Zgaga2,8,
Caroline Hayward 9, Archie Campbell 10, Sarah Harris10,11,12, Ian J. Deary10,11, John Starr10,13,14,
Laura Gatcombe4, Maria Pinna4, Sarah Briggs4, Lynn Martin 4, Emma Jaeger4, Archana Sharma-Oates4,
James East 15, Simon Leedham5,14, Roland Arnold16, Elaine Johnstone17, Haitao Wang17, David Kerr18,
Rachel Kerr17, Tim Maughan17, Richard Kaplan 19, Nada Al-Tassan 20, Kimmo Palin 21, Ulrika A. Hänninen21,
Tatiana Cajuso21, Tomas Tanskanen21, Johanna Kondelin21, Eevi Kaasinen21, Antti-Pekka Sarin22,
Johan G. Eriksson23,24, Harri Rissanen25, Paul Knekt25, Eero Pukkala26,27, Pekka Jousilahti25,
Veikko Salomaa 25, Samuli Ripatti22,28,29, Aarno Palotie22,30, Laura Renkonen-Sinisalo31, Anna Lepistö31,
Jan Böhm32, Jukka-Pekka Mecklin33,34, Daniel D. Buchanan 35,36,37, Aung-Ko Win 38, John Hopper38,
Mark E. Jenkins 38, Noralane M. Lindor39, Polly A. Newcomb40, Steven Gallinger41, David Duggan42,
Graham Casey43, Per Hoffmann44,45, Markus M. Nöthen45,46, Karl-Heinz Jöckel47, Douglas F. Easton 48,49,
Paul D.P. Pharoah 48,49, Julian Peto50, Federico Canzian51, Anthony Swerdlow1,52, Rosalind A. Eeles 1,53,
Zsoﬁa Kote-Jarai1, Kenneth Muir 54,55, Nora Pashayan 56,57, The PRACTICAL consortium,
Andrea Harkin 58, Karen Allan58, John McQueen58, James Paul 58, Timothy Iveson59, Mark Saunders60,
Katja Butterbach61, Jenny Chang-Claude62,63, Michael Hoffmeister61, Hermann Brenner61,64,65, Iva Kirac66,
Petar Matošević67, Philipp Hofer 68, Stefanie Brezina 68, Andrea Gsur68, Jeremy P. Cheadle 69,
Lauri A. Aaltonen21, Ian Tomlinson 4, Richard S. Houlston 1 & Malcolm G. Dunlop2
1Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK. 2Colon Cancer Genetics Group, Medical Research
Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh EH4
2XU, UK. 3Grupo de Medicina Xenómica, Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación de Santiago, Santiago de
Compostela 15706, Spain. 4Cancer Genetics and Evolution Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham,
Vincent Drive, Edgbaston, Birmingham B15 2TT, UK. 5Wellcome Centre for Human Genetics, McCarthy Group, Roosevelt Drive, Oxford OX3 7BN,
UK. 6Gastrointestinal Cancer Genetics Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston,
Birmingham B15 2TT, UK. 7Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh EH8 9AG, UK. 8Department of
Public Health and Primary Care, Institute of Population Health, Trinity College Dublin, University of Dublin, Dublin D02 PN40, Ireland. 9Medical
Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh,
Edinburgh EH4 2XU, UK. 10Generation Scotland, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK. 11Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh,
Edinburgh EH8 9JZ, UK. 12Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK. 13Medical Genetics Section, Centre for
Genomics and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK. 14Alzheimer
Scotland Dementia Research Centre, University of Edinburgh, Edinburgh EH8 9JZ, UK. 15Translational Gastroenterology Unit, Nufﬁeld Department.
of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. 16Cancer Bioinfomatics Laboratory, Institute of Cancer and
Genomic Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK. 17Department of Oncology, University of Oxford,
Old Road Campus Research Building, Oxford OX3 7LE, UK. 18Nufﬁeld Department of Clinical Laboratory Sciences, John Radcliffe Hospital,
University of Oxford, Oxford OX3 9DU, UK. 19Medical Research Council Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
20Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia. 21Department of Medical and Clinical
Genetics, Medicum and Genome-Scale Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki 00014, Finland.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications 13
22Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki 00014, Finland. 23Folkhälsan Research Centre, 00250 Helsinki,
Finland. 24Unit of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland.
25National Institute for Health and Welfare, Helsinki 00271, Finland. 26Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer
Research, Helsinki, Finland, and Faculty of Social Sciences, University of Tampere, Tampere 33014, Finland. 27Faculty of Social Sciences, University
of Tampere, Tampere 33014, Finland. 28Department of Public Health, University of Helsinki, Helsinki 00014, Finland. 29Broad Institute of MIT and
Harvard, Cambridge, MA 02142, USA. 30Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital,
Boston, MA 02114, USA. 31Department of Surgery, Abdominal Center, Helsinki University Hospital, Helsinki 00029, Finland. 32Department of
Pathology, Central Finland Central Hospital, Jyväskylä 40620, Finland. 33Department of Surgery, Jyväskylä Central Hospital, Jyväskylä 40620,
Finland. 34Department of Health Sciences, Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä 40014, Finland. 35Colorectal
Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria 3010, Australia. 36Victorian
Comprehensive Cancer Centre, University of Melbourne, Centre for Cancer Research, Parkville, Victoria 3010, Australia. 37Genomic Medicine and
Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC 3010, Australia. 38Centre for Epidemiology and Biostatistics, The University of
Melbourne, Melbourne, VIC 3010, Australia. 39Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ 85259, USA. 40Cancer
Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. 41Mount Sinai Hospital, Lunenfeld-Tanenbaum Research
Institute, Toronto ON M5G 1X5, Canada. 42Translational Genomics Research Institute (TGen), An Afﬁliate of City of Hope, Phoenix, AZ 85004,
USA. 43Center for Public Health Genomics, University of Virginia, Virginia, VA 22903, USA. 44Human Genomics Research Group, Department of
Biomedicine, University of Basel, Basel 4031, Switzerland. 45Department of Genomics, Life & Brain Center, University of Bonn, Bonn 53127,
Germany. 46Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn 53127, Germany. 47Institute for
Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen 45147, Germany. 48Centre for
Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. 49Centre for Cancer Genetic
Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. 50Department of Non-
Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK. 51Genomic Epidemiology Group,
German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. 52Division of Breast Cancer Research, The Institute of Cancer Research,
London SW3 6JB, UK. 53Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. 54Division of Population Health, Health Services Research and
Primary Care, University of Manchester, Manchester M13 9PL, UK. 55Warwick Medical School, University of Warwick, Coventry CV4 7HL, UK.
56Department of Applied Health Research, University College London, London WC1E 7HB, UK. 57Centre for Cancer Genetic Epidemiology,
Department of Oncology, Strangeways Laboratory, University of Cambridge, Cambridge CB1 8RN, UK. 58Cancer Research UK Clinical Trials Unit,
Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1BD, UK. 59University Hospital Southampton NHS Foundation Trust,
Southampton SO16 6YD, UK. 60The Christie NHS Foundation Trust, Manchester M20 4BX, UK. 61Division of Clinical Epidemiology and Aging
Research, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany. 62Unit of Genetic Epidemiology, German Cancer Research Center
(DKFZ), Heidelberg 69120, Germany. 63University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg 20251,
Germany. 64German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany. 65Division of Preventive
Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg 69120, Germany. 66Department of
Surgical Oncology, University Hospital for Tumours, Sestre milosrdnice University Hospital Centre, Zagreb 10000, Croatia. 67Department of
Surgery, University Hospital Center Zagreb, 10000 Zagreb, Croatia. 68Department of Medicine I, Institute of Cancer Research, Medical University of
Vienna, Borschkegasse 8a, 1090 Vienna, Austria. 69Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK.
These authors contributed equally: Philip J. Law, Maria Timofeeva, Ceres Fernandez-Rozadilla. These authors jointly supervised this work: Ian
Tomlinson, Richard S. Houlston, Malcolm G. Dunlop. Additional members from the Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome (PRACTICAL) consortium are listed below.
The PRACTICAL consortium
Brian E. Henderson70, Christopher A. Haiman70, Fredrick R. Schumacher71,72, Ali Amin Al Olama57,73,
Sara Benlloch1,57, Sonja I. Berndt74, David V. Conti70, Fredrik Wiklund75, Stephen Chanock70, Susan Gapstur76,
Victoria L. Stevens76, Catherine M. Tangen77, Jyotsna Batra78,79, Judith Clements78,79, Henrik Gronberg75,
Johanna Schleutker80,81, Demetrius Albanes74, Alicja Wolk82,83, Catharine West84, Lorelei Mucci85,
Géraldine Cancel-Tassin86,87, Stella Koutros74, Karina Dalsgaard Sorensen88,89, Eli Marie Grindedal90,
David E. Neal91,92,93,94, Freddie C. Hamdy93,94, Jenny L. Donovan95, Ruth C. Travis96, Robert J. Hamilton97,
Sue Ann Ingles70, Barry S. Rosenstein98,99, Yong-Jie Lu100, Graham G. Giles101,102, Adam S. Kibel103,
Ana Vega104, Manolis Kogevinas105,106,107,108, Kathryn L. Penney109, Jong Y. Park110, Janet L. Stanford111,112,
Cezary Cybulski113, Børge G. Nordestgaard114,115, Christiane Maier116, Jeri Kim117, Esther M. John118,119,
Manuel R. Teixeira120,121, Susan L. Neuhausen122, Kim De Ruyck123, Azad Razack124, Lisa F. Newcomb111,125,
Marija Gamulin126, Radka Kaneva127, Nawaid Usmani128,129, Frank Claessens130, Paul A. Townsend131,
Manuela Gago-Dominguez3,132, Monique J. Roobol133, Florence Menegaux134, Kay-Tee Khaw135,
Lisa Cannon-Albright136,137, Hardev Pandha138 & Stephen N. Thibodeau139
70Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los
Angeles, CA 90033, USA. 71Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44106, USA.
72Seidman Cancer Center, University Hospitals, Cleveland, OH 44106, USA. 73Department of Clinical Neurosciences, University of Cambridge,
Cambridge CB2 1TN, UK. 74Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w
14 NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications
75Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm 30303, Sweden. 76Epidemiology Research Program,
American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA. 77SWOG Statistical Center, Fred Hutchinson Cancer Research Center,
Seattle, WA 98109, USA. 78Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of
Biomedical Science, Queensland University of Technology, Brisbane 4059 Queensland, Australia. 79Translational Research Institute, Brisbane 4102
Queensland, Australia. 80Department of Medical Biochemistry and Genetics, Institute of Biomedicine, University of Turku, Turku 20520, Finland.
81Tyks Microbiology and Genetics, Department of Medical Genetics, Turku University Hospital, Turku 20520, Finland. 82Division of Nutritional
Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm 171 77, Sweden. 83Department of Surgical Sciences, Uppsala
University, Uppsala 751 85, Sweden. 84Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre,
Radiotherapy Related Research, Manchester NIHR Biomedical Research Centre, The Christie Hospital NHS Foundation Trust, Manchester M13
9NT, UK. 85Department of Epidemiology, Harvard T.H Chan School of Public Health, Boston, MA 02115, USA. 86CeRePP, Tenon Hospital, Paris
75020, France. 87Sorbonne Université, GRC n°5 ONCOTYPE-URO, Tenon Hospital, Paris 75970, France. 88Department of Molecular Medicine,
Aarhus University Hospital, Aarhus 8000, Denmark. 89Department of Clinical Medicine, Aarhus University, Aarhus 8000, Denmark. 90Department
of Medical Genetics, Oslo University Hospital, Oslo 0424, Norway. 91Department of Oncology, Addenbrooke’s Hospital, University of Cambridge,
Cambridge CB2 0QQ, UK. 92Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. 93Nufﬁeld
Department of Surgical Sciences, University of Oxford, Oxford OX3 7LF, UK. 94Faculty of Medical Science, John Radcliffe Hospital, University of
Oxford, Oxford OX3 9DU, UK. 95School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK. 96Cancer Epidemiology Unit,
Nufﬁeld Department of Population Health University of Oxford, Oxford OX3 7LF, UK. 97Department of Surgical Oncology, Princess Margaret Cancer
Centre, Toronto M5G 2M9, Canada. 98Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
99Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. 100Centre for Molecular
Oncology, Barts Cancer Institute, John Vane Science Centre, Queen Mary University of London, London EC1M 6BQ, UK. 101Cancer Epidemiology &
Intelligence Division, The Cancer Council Victoria, Melbourne 3004 Victoria, Australia. 102Centre for Epidemiology and Biostatistics, Melbourne
School of Population and Global Health, The University of Melbourne, Melbourne 3053, Australia. 103Division of Urologic Surgery, Brigham and
Womens Hospital, Boston, MA 02115, USA. 104Fundación Pública Galega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica, CIBERER,
IDIS, Santiago de Compostela 15782, Spain. 105Centre for Research in Environmental Epidemiology (CREAL), Barcelona Institute for Global Health
(ISGlobal), Barcelona 60803, Spain. 106CIBER Epidemiología y Salud Pública (CIBERESP), Madrid 28029, Spain. 107IMIM (Hospital del Mar
Research Institute), Barcelona 08003, Spain. 108Universitat Pompeu Fabra, Barcelona 08002, Spain. 109Channing Division of Network Medicine,
Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA 02115, USA. 110Department of Cancer
Epidemiology, Mofﬁtt Cancer Center, Tampa 33612, USA. 111Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle
98109 Washington, USA. 112Department of Epidemiology, School of Public Health, University of Washington, Seattle 98195 Washington, USA.
113International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-001, Poland.
114Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 1165, Denmark. 115Department of Clinical Biochemistry, Herlev
and Gentofte Hospital, Copenhagen University Hospital, Herlev 2900, Denmark. 116Institute for Human Genetics, University Hospital Ulm, Ulm
89081, Germany. 117Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030,
USA. 118Cancer Prevention Institute of California, Fremont, CA 94538, USA. 119Department of Health Research & Policy (Epidemiology) and
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. 120Department of Genetics, Portuguese Oncology
Institute of Porto, Porto 4200-072, Portugal. 121Biomedical Sciences Institute (ICBAS), University of Porto, Porto 4200-072, Portugal.
122Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA 91016, USA. 123Faculty of Medicine and Health
Sciences, Basic Medical Sciences, Ghent University, Gent 9000, Belgium. 124Faculty of Medicine, Department of Surgery, University of Malaya,
Kuala Lumpur 50603, Malaysia. 125Department of Urology, University of Washington, Seattle, WA 98105, USA. 126Division of Medical Oncology,
Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, 10 000 Zagreb, Croatia. 127Molecular Medicine Center, Department
of Medical Chemistry and Biochemistry, Medical University, Soﬁa 1431, Bulgaria. 128Department of Oncology, Cross Cancer Institute, University of
Alberta, Edmonton T6G 2R3 Alberta, Canada. 129Division of Radiation Oncology, Cross Cancer Institute, Edmonton T6G 1Z2 Alberta, Canada.
130Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven 3000 Leuven, Belgium. 131Institute of Cancer
Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester Academic Health Science Centre, St Mary’s Hospital,
Manchester M13 9WL, UK. 132University of California San Diego, Moores Cancer Center, La Jolla, CA 92093, USA. 133Department of Urology,
Erasmus University Medical Center, Rotterdam 3015, the Netherlands. 134Cancer & Environment Group, Center for Research in Epidemiology and
Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif 94805, France. 135Clinical Gerontology Unit, University of
Cambridge, Cambridge CB2 2QQ, UK. 136Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt
Lake City, UT 84108-1266, USA. 137George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA. 138The
University of Surrey, Guildford GU2 7XH Surrey, UK. 139Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905,
USA
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09775-w ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2154 | https://doi.org/10.1038/s41467-019-09775-w |www.nature.com/naturecommunications 15
